Under the Paperwork Reduction Act of 1994, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b)

Attorney Docket No.: 2003-1243A

First Named Inventor: Kazuhiro YOSHIDA et al.

Title: PRODUCTION PROCESS FOR SILSESQUIOXANE DERIVATIVE HAVING FUNCTIONAL GROUP AND SILSESQUIOXANE DERIVATIVE

Express Mail Label No .:

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. [X] Fee Transmittal Form

(Submit an original, and a duplicate for fee processing)

2. [] Small Entity Status is hereby asserted.

3. [X] Specification [Total Pages: 103]

(preferred arrangement set forth below)

- Descriptive title of the Invention
- **Cross References to Related Applications**
- Statement Regarding Fed sponsored R & D
- Reference to Sequence Listing, a table, or a computer program listing appendix.
- Background of the Invention
- **Brief Summary of the Invention**
- Brief Description of the Drawings (if filed)
- **Detailed Description**
- Claim(s)
- **Abstract of the Disclosure**

4. [] Drawing(s) (35 USC 113)

[Total Sheets:] [Total Pages: 4]

- 5. [X] Oath or Declaration
 - a.1. [X] Newly executed (original or copy)
 - a.2. [] Unexecuted
 - b. [] Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)
 - i. [] DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. [] Application Data Sheet (see 37 CFR 1.76)

Commissioner for Patents

ADDRESS TO: P.O. Box 1450

Alexandria, VA 22313-1450

7. [] CD-ROM or CD-R in duplicate, large table or computer program (Appendix)

8. [] Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

- a. [] Computer Readable Form
- b. Specification Sequence Listing on:
 - i. [] CD-ROM or CD-R (2 copies); or
 - ii. [] Paper
- c. [] The paper and computer readable copies are identical

ACCOMPANYING APPLICATION PARTS

- 9. [X] Assignment Papers (cover sheet & document(s))
- 10. [] 37 CFR 3.73(b) Statement (when there is an assignee)
- [] Power of Attorney
- 11. [] English Translation Document (if applicable)
- 12. [X] Information Disclosure Statement (IDS)/PTO-1449 [X] Copies of IDS Citations
- 13. [X] Preliminary Amendment
- 14. [X] Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- 15. [X] Certified Copy of Priority Document(s) (2) (if foreign priority is claimed)
- 16. [] Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
- 17. [X] Other Claim of Priority

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below, and in a preliminary amendment, or in an Application Data Sheet:

[] Continuation

[] Divisional

[] Continuation-in-part (CIP)

of prior application No.

Prior Application Information: Examiner

Group Art Unit

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference therein. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

CUSTOMER NO.

000513

Registration No. 25,134

WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone:(202) 721-8200 Fax:(202) 721-8250

THE COMMISSIONER AUTHORIZED

September 15, 2003

TO CHARGE ANT DEFI FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

09/15/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Kazuhiro YOSHIDA et al.

Serial No. NEW : Attn: APPLICATION BRANCH

Filed September 15, 2003 : Attorney Docket No. 2003-1243A

PRODUCTION PROCESS FOR SILSESQUIOXANE DERIVATIVE HAVING FUNCTIONAL GROUP AND SILSESQUIOXANE DERIVATIVE

PATENT OFFICE FEE TRANSMITTAL FORM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

Attached hereto is a check in the amount of \$1,324.00 to cover Patent Office fees relating to filling the following attached papers:

Additional Claims Fee:

Excess of Twenty \$\frac{198.00}{336.00}\$

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Kazuhiro YOSHIDA et al.

Michael B. Dour

Registration No. 25,134

Attorney for Applicants

MRD/pth
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
September 15, 2003

[Check No. <u>57628</u>

2003-1243A